# Obsidian Therapeutics Inc. (OBX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.82, market value $1.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Obsidian Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -8.7%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 37.8%**. 37.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -21.1%**. Earnings per share fell 21.1%.

## Financial health
- **Current ratio: 5.31** (quick 5.31). Current assets cover the next year's liabilities 5.31 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Obsidian Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -66.3%** (15.4% above the low). Trading 66% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 48**. An RSI of 48 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=OBX · Page: https://foliofundamentals.com/stocks/obx

Not investment advice.